Feedback
Settings

Settings

Goto Application

989,035 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 98,904
1.WO/2026/017727ALTERNATIVE BARCODING METHOD TO ASSESS TRANSDUCTION EFFICIENCY OF AAV VECTORS
WO - 22.01.2026
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
 Appl.No PCT/EP2025/070307 Applicant GENETHON Inventor LEBORGNE, Christian
The invention relates to a barcoding method to assess transduction efficiency of AAV vectors, in particular in vivo in rodent and non-human primate.
2.WO/2026/019692IMMUNOMODULATORY FUSION PROTEINS AND RELATED METHODS
WO - 22.01.2026
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
 Appl.No PCT/US2025/037499 Applicant FLAGSHIP PIONEERING INNOVATIONS VII, LLC Inventor BANDUKWALA, Hozefa Saifuddin
Provided herein are immunomodulatory fusion proteins and compositions (e.g., pharmaceutical compositions) comprising the same; as well as methods of making the immunomodulatory fusion proteins and compositions. The immunomodulatory fusion proteins provided herein are useful in pharmaceutical compositions and methods of use (including, e.g., methods of suppressing or reducing (e.g., preventing) a pro-inflammatory immune response in a subject).
3.WO/2026/019797METHODS FOR TREATING WET AGE-RELATED MACULAR DEGENERATION WITH ADENO-ASSOCIATED VIRUS
WO - 22.01.2026
Int.Class A61K 38/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
18Growth factors; Growth regulators
 Appl.No PCT/US2025/037706 Applicant 4D MOLECULAR THERAPEUTICS, INC. Inventor KIM, Robert Young
Pharmaceutical compositions comprising adeno-associated virus (AAV) and their use in treating wet age-related macular degeneration are provided herein. In some aspects, treatment methods encompass co-administration of one or more corticosteroids and/or supplemental administrations of aflibercept protein.
4.WO/2026/020022MULTISPECIFIC BINDING AGENTS AND USES THEREOF
WO - 22.01.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/038086 Applicant BAMBUSA THERAPEUTICS, INC. Inventor CHEN, Yuanhong
The present application relates to multispecific binding agents and uses thereof, specifically multispecific binding agents that bind to both interleukin-4 receptor alpha (IL-4Rα) and interleukin 31 (IL-31). The present application further provides compositions (e.g., pharmaceutical compositions) comprising the multispecific binding agents provided herein and uses thereof.
5.WO/2026/019782METHODS FOR REDUCING FILTER FOULING IN PERFUSION CELL CULTURES WITH RECIRCULATING TANGENTIAL FLOW FILTRATION
WO - 22.01.2026
Int.Class C12P 21/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21Preparation of peptides or proteins
02having a known sequence of two or more amino acids, e.g. glutathione
 Appl.No PCT/US2025/037680 Applicant AMGEN INC. Inventor RAJU, Ravali T.
The present disclosure provides methods for producing recombinant proteins (e.g., antibodies) in mammalian cell culture under conditions that limit filter fouling and enable robust recirculating tangential flow (RTF) filtration operation in perfusion processes in which the working volume is increased to a final working volume during the cell culture.
6.WO/2026/016001ANTI-ANG2 MONOSPECIFIC AND MULTISPECIFIC ANTIBODY CONSTRUCTS
WO - 22.01.2026
Int.Class C07K 16/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
 Appl.No PCT/CN2024/105503 Applicant QUAERITE BIOPHARM RESEARCH (BEIJING) CO., LTD. Inventor HUANG, Jinliang
Provided is an anti-neovascular therapy. More particularly, provided are anti-angiopoietin 2 (ANG2) antibodies or antigen binding fragments, which may be constructed as monospecific antibodies, or bispecific antibodies or fusion proteins (e.g., targeting human ANG2 and human serum albumin (HSA) ), or multifunctional fusion proteins, for example targeting ANG2, human vascular endothelial growth factor (VEGF), and HSA. In other aspects, methods for the production of these monospecific, bispecific, and multi-specific polypeptides, pharmaceutical compositions containing said antibodies and polypeptides, and uses thereof for treating neovascular disease are also provided.
7.WO/2026/016166DIFFERENTIAL GENE EXPRESSION REGULATION SYSTEM IN RESPONSE TO HYPOXIA ENVIRONMENT AND USE THEREOF
WO - 22.01.2026
Int.Class C12N 15/867
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
867Retroviral vectors
 Appl.No PCT/CN2024/106406 Applicant SHANGHAI SINOBAY BIOTECHNOLOGY CO., LTD. Inventor XU, Jianqing
Provided are a differential gene expression regulation system in response to a hypoxia environment and a use thereof. The gene expression regulation system comprises: a hypoxia-sensitive promoter, a target gene expression cassette, and a polynucleotide encoding a truncated oxygen-dependent degradation domain, which can be effectively used in CAR-T immune cell therapy. Since a CAR structure comprises a promoter specifically activated under hypoxia conditions, a CAR functional sequence, and the truncated oxygen-dependent degradation domain, the target killing activity of transduced CAR-T cells in a hypoxia environment is enhanced, thereby achieving good safety while ensuring the effective treatment of CAR-T, and having broad application values and prospects.
8.WO/2026/016811ANTI-TFR1 ANTIBODY, AND ANTIGEN-BINDING FRAGMENT THEREOF OR HUMANIZED ANTIBODY THEREOF, AND USE THEREOF
WO - 22.01.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/CN2025/104864 Applicant CHAINGEN BIOPHARMA LTD Inventor XING, Yafei
Using rabbit antibody technology, an anti-TfR1 monoclonal antibody having high affinity, high specificity and high blood safety is obtained by means of phage immune library construction and screening, and the anti-TfR1 monoclonal antibody is subjected to humanization and affinity maturation treatment to obtain a humanized anti-TfR1 monoclonal antibody having high affinity without inducing immunogenicity.
9.WO/2026/017126USE OF ARTIFICIALLY DESIGNED NOVEL NRG-1 IN DISEASE TREATMENT
WO - 22.01.2026
Int.Class C12N 15/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
 Appl.No PCT/CN2025/109129 Applicant TIANJIN MEDICAL UNIVERSITY Inventor CHEN, Xiongwen
The present invention provides an artificially designed novel NRG-1 nucleic acid molecule, a protein variant thereof, a vector, a vaccine, a cell, a pharmaceutical composition, and a protein composition. Also provided are a method for using the product to produce a protein and a primary RNA polynucleotide, and a use in preparation of a product for preventing, alleviating or treating cardiovascular diseases and neurological diseases, a product for maintaining normal functions of heart cells or tissues, and a vaccine.
10.WO/2026/017141METHOD FOR REPRESENTING TARGET BIOMOLECULE
WO - 22.01.2026
Int.Class C12Q 1/6869
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6869Methods for sequencing
 Appl.No PCT/CN2025/109282 Applicant QITAN TECHNOLOGY LTD., BEIJING Inventor LIU, Ce
Provided are a method for representing a target biomolecule, a ligation method or a preparation method for a sequencing library, an activation linker, a method for preparing the activation linker, a kit for nanopore sequencing, and a use of the activation linker in nanopore sequencing.
# -